1. Introduction {#s0005}
===============

Obesity, caused by an imbalance between energy intake and energy expenditure, has become a global health crisis ([@bb0060]). Brown adipose tissue (BAT) found prominently in rodents and hibernating mammals functions to dissipate energy in the form of non-shivering thermogenesis mediated by the uncoupling protein Ucp1 ([@bb0035], [@bb0080]). Adult humans also have functional BAT with the capacity to take up and utilize glucose and fatty acids for thermogenesis ([@bb0050], [@bb0105], [@bb0120], [@bb0130], [@bb0140], [@bb0230], [@bb0235]). It has been demonstrated that repeated cold treatments activate human BAT in parallel to an increase in energy expenditure ([@bb0225], [@bb0260]). As such, BAT represents a promising target in the treatment of obesity and other metabolic disorders. However, BAT abundance decreases with age ([@bb0050], [@bb0105], [@bb0140], [@bb0230], [@bb0235]). Understanding the molecular regulation of BAT biogenesis is key to the development of novel approaches to expand BAT mass.

Brown adipocytes and myoblasts are derived from a common pool of progenitors expressing Myf5 ([@bb0195]), the earliest myogenic regulatory factor (MRF) detected in developing muscles ([@bb0125]). The fate of brown adipocytes is determined by the expression of PR domain containing protein 16 (Prdm16) ([@bb0195]). Ectopic expression of Prdm16 in myoblasts inhibits myogenesis and the expressions of muscle related genes, partly through euchromatic histone-lysine *N*-methyltransferase 1 and miR-193b-365 ([@bb0110], [@bb0195], [@bb0200]). MRFs, including Myf5, MyoD, Myog and Myf6 (Mrf4) orchestrate the process of myogenesis ([@bb0115], [@bb0150]). MyoD acts downstream of Myf5 to commit somite-derived cells to myoblasts ([@bb0175]), and to initiate the onset of myogenic differentiation ([@bb0165]). A lineage-tracing study reveals that the MyoD lineage does not give rise to brown adipocytes ([@bb0190]), indicating a role of MyoD in myogenic cell fate switch in the common Myf5^+^ progenitors that give rise to both myoblasts and brown preadipocytes. However, whether loss of MyoD promotes brown adipocyte cell fate conversion of myoblasts, and whether ectopic expression of MyoD in brown preadipocytes inhibits adipogenesis has not been examined. In this paper, we provide gain- and loss-of-function evidence to show that MyoD acts as a key molecular repressor of the brown adipocyte cell fate.

2. Materials and Methods {#s0010}
========================

2.1. Animals {#s0015}
------------

MyoD^−/−^ mice ([@bb0170]) were generously provided by Dr. Michael Rudnicki (Ottawa Health Research Institute, Ottawa, Ontario, Canada). The miR-133a1/a2 double knockout mice were generously provided by Dr. Eric Olson ([@bb0085]). The mdx mice (stock\#001801, RRID: IMSR_JAX:001801) and MyoD^iCre/+^ mice (stock\#014140) were from Jackson lab. Mice were housed in the animal facility with free access to water and standard rodent chow. All procedures involving the use of animals were performed in accordance with the guidelines presented by Purdue University\'s Animal Care and Use Committee. Unless otherwise indicated, 2-month-old adult mice were used in this study.

2.2. Generation of MyoD-Knockout C2C12 Cell Lines {#s0020}
-------------------------------------------------

### 2.2.1. Generation of Cas9-Overexpressing C2C12 Cells {#s0025}

We utilized the CRISPR-Cas9 technique to mutate the MyoD gene in C2C12 cell line. To examine the efficiency of gRNAs, we generated a C2C12 cell line with Cas9 overexpressing by transfecting cells with the plasmid PX459 ([@bb0155]). PX459 contains the Cas9 protein with a FLAG tag and a puromycin resistant gene. Puromycin (1 μg/ml) selection was used to purify cells transfected with PX459, and FLAG antibody was used to verify the expression of Cas9 in C2C12 cells (C2C12^Cas9^).

### 2.2.2. Selection of gRNA Targets {#s0030}

We used CRISPR Design (<http://crispr.mit.edu/>) to choose gRNA targets of *MyoD* ([@bb0155]). The gRNAs were generated by *in vitro* transcription according to the online protocol (http://www.[crisprflydesign.org/grnatranscription](http://crisprflydesign.org/grnatranscription){#ir0010}/). Then the gRNAs (1 μg for each gRNA/10^6^ cells) were electroporated into C2C12^Cas9^ cells. For the control sample, we only gave C2C12^Cas9^ cells electric shocks. One day after the electroporation, we collected the cells, extracted DNA and amplified the region around the target sites by PCR. Clones containing cleaved bands in the gRNA treated sample but not in the control sample were sequenced to confirm correct targeting.

### 2.2.3. MyoD KO Cell Line Selection {#s0035}

We chose the gRNA target close to the 5′ of the *MyoD* gene and cloned it into the PX459 plasmid (PX459^MyoD^). Wildtype C2C12 cells were electroporated with PX459^MyoD^ or PX459 (1 μg/10^6^ cell). Two days after electroporation, puromycin (1 μg/ml) was added to the culture medium. Five days after puromycin selection, the remaining cells electroporated with PX459 were collected as control for the following studies. The remaining cells electroporated with PX459^MyoD^ were detached by 0.25% trypsin and transferred to 48-well plates by serial dilution. When the cell confluency was over 70%, cells were passaged and parts of them were used to do DNA extraction, PCR amplification and sequencing. Cells containing predicted genomic alteration were cloned a second time to achieve homogeneity.

### 2.2.4. Off-target Detection {#s1035}

The gRNA off-targets were searched by CRISPR Design. None of the 10 most likely off-target sites by the gRNA selected in this study were located in the gene body. The top 5 potential off-target sites (Table S1) were PCR amplified using genomic DNA as templates. The PCR products were subjected to T7EN1 cleavage assay. The potential off-target sites yielding typical cleavage bands were considered as candidates. Primers for PCR amplification of off-target sites were listed in Table S2.

2.3. Primary Adipocyte Isolation, Culture and Differentiation {#s0040}
-------------------------------------------------------------

Interscapular BAT depots from wildtype or miR-133a mutant mice were collected, minced and digested with isolation buffer (DMEM supplemented with 1.5 mg/ml Collagenase I) for proper time at 37 °C on a shaker. The digestion was stopped with DMEM containing 10% FBS, filtered through 100 μm filters, and cells were pelleted at 450 ×* g* for 5 min. The cells were cultured in growth media containing DMEM, 20% FBS and 1% P/S at 37 °C with 5% CO~2~ for 3 days, and then fresh media was changed every 2 days. Upon confluence, cells were exposed to induction media and then differentiation media. C2C12 cells were exposed to induction media for 2 days and differentiation media for 3 days. Satellite cell-derived myoblasts were exposed to induction media for 6 days and differentiation media for 6 days. Brown preadipocytes were exposed to induction media for 4 days and differentiation media for 4 days. The induction media contains DMEM, 10% FBS, 2.85 μM insulin, 0.3 μM dexamethasone and 0.63 mM 3-isobutyl-1-methylxanthine (Sigma), and the differentiation media contains DMEM, 10% FBS, 200 nM insulin and 10 nM T3. For C2C12 cells and Satellite cell-derived myoblasts, we also add 1 μM Rosiglitazone to the induction media and differentiation media. The miR-133a *mir*Vana miRNA mimic was purchased from Ambion. The Akt dominant negative plasmid, GFP-Akt-K179M was a kind gift from Dr. Xiaoqi Liu ([@bb0040]). The PI3K inhibitor (LY294002) was purchased from Sigma and used to treat C2C12 myoblasts during adipogenic induction at 10 μM concentration.

2.4. Oil Red O Staining {#s0045}
-----------------------

Cells or muscle sections were rinsed with PBS and fixed with 10% formaldehyde for 15 min at room temperature. Cells or muscle sections were stained in working solution containing 6 ml of Oil Red O (ORO) stock solution (5 mg/ml in isopropanol) and 4 ml ddH~2~O for 60 min. After staining, slides were washed with distilled water for 10 min and mounted in glycerol mounting medium.

2.5. Muscle Injury and Myoblasts Transplantation {#s0050}
------------------------------------------------

Muscle regeneration was induced by cardiotoxin (CTX; Sigma-Aldrich) or glycerol (Macron Fine Chemicals) injection. Mice were first anesthetized using a ketamine-xylazine cocktail and then the TA muscles were bilaterally injured with 50 μl of 10 μM CTX or 50 μl 50% glycerol. Two days after the CTX or glycerol injury, we injected 50 μl concentrated adenovirus (1 × 10^6^ cells) into injured TA muscles. For comparable results, the left and right TA muscles were injected with control and MyoD^KO^ C2C12 myoblasts, respectively. The concentrations of triglyceride in TA muscles were measured using the Triglyceride Colorimetric Assay Kit (Cayman). Glycerol is able to degenerate and induce adipogenesis of skeletal muscle ([@bb0145]). TA muscle injection with glycerol was performed to induce adipogenic induction of 2--3 month old wild-type and *MyoD*^*−/−*^ mice. Ten days after injection, muscle tissues were harvested for ORO staining and RNA isolation.

2.6. Primary Myoblast Isolation, Culture and Differentiation {#s0055}
------------------------------------------------------------

TA muscle was harvested, and satellite cell-derived primary myoblasts were isolated as described previously ([@bb0100]). Briefly, TA muscles of MyoD^−/−^ mice or their wild-type littermates were dissected and minced and then digested in type I collagenase/dispase B mixture (Roche Applied Science). The digestions were filtered from debris for magnetic-activated cell sorting (MACS). Dissociated muscle cells were incubated with Anti-CD45-PE, *anti*-Sca-1-PE and anti-CD31-PE antibodies (all from eBiosciences) followed by anti-PE beads (Miltenyi Biotec). LD column (Miltenyi Biotec) was used for negative selection to eliminate hematopoietic cells, endothelial cells and other non-muscle cells from the muscle preparation. Flow through fraction was incubated with integrin α-biotin antibody (Miltenyi Biotec) followed by anti-biotin beads (Miltenyi Biotec). MS column (Miltenyi Biotec) was used for primary myoblast isolation as a positive fraction. Isolated primary myoblasts were cultured in growth media (F-10 Ham\'s media supplemented with 17% FBS, 4 ng/ml basic fibroblast growth factor and 1% penicillin-streptomycin) on collagen-coated dishes, and the growth medium was changed every two days. Primary myoblasts were cultured in normal humidified tissue culture incubators with 5% CO~2~.

2.7. Adenovirus Generation {#s0060}
--------------------------

The adenovirus with *MyoD* insertion was generated using the AdEasy system. Briefly, the *MyoD* ORF was cloned using pairs of primers (MyoD-f and MyoD-r, Table S2), and inserted into pAdTrack-CMV plasmid. The formed pAdTrack-CMV-*MyoD* (pAdTrack-CMV as the control) plasmids were digested by *Pme*I and then transfected the DH5a competent cell with pAdEasy-1. The positive recombinant plasmid was detected by *Pac*I digestion. Then, 293A cells (60%--70% confluent) in 10 cm culture dishes was transfected with the 4 μg *Pac*I digested recombinant plasmid using Lipofectamine 2000 (Life Technologies) according to manufacturer\'s protocol. After 14 days incubation, the recombinant adenovirus was released by four freeze--thaw--vortex cycles. Two more round infections were adapted to amplify the recombinant virus and the titers were determined by the expression of GFP.

2.8. Immunostaining and Image Acquisition {#s0065}
-----------------------------------------

Myoblasts were fixed with 4% paraformaldehyde, and blocked with blocking buffer (5% goat serum, 2% BSA, 0.2% triton X-100, and 0.1% sodium azide in PBS) for at least 1 h. The samples were then incubated with primary antibody \[MyoD (M318, RRID: [AB_2148870](nif-antibody:AB_2148870){#ir0015}) was from Santa Cruz and Perilipin (D1D8, RRID: [AB_10621999](nif-antibody:AB_10621999){#ir0020}) was from Cell Signaling\] in blocking buffer overnight. After washing with PBS, the samples were incubated with secondary antibodies and DAPI or BODIPY 493/503 for 45 min at room temperature. Fluorescent images were captured using a Leica DM 6000B fluorescent microscope. As the adenoviral vectors contain *GFP* and thus express green signals when they are transduced into cells, we calculated the number of different signals only in GFP^+^ cells.

2.9. Total RNA Extraction, cDNA Synthesis, and Real-Time PCR {#s0070}
------------------------------------------------------------

Total RNA was extracted from cells using Trizol Reagent according to the manufacturer\'s protocols. RNA was treated with RNase-free DNase I to remove contaminating genomic DNA. The purity and concentration of total RNA were measured by Nanodrop 3000 (Thermo Fisher). Random primers and Moloney murine leukemia virus reverse transcriptase were used to convert RNA into cDNA. For microRNA, multiple adenosine nucleotides were added to 3′ end of RNAs by *E. coli* DNA polymerase and cDNAs were synthesized with a specific RT primer ([@bb0095]). Real-time PCR was performed using Roche Lightcycler 480 PCR System with SYBR Green Master Mix and gene-specific primers described previously ([@bb0200], [@bb0240]). Ct value of *18S* rRNA and U6 snRNA was used to normalize mRNA and miRNA expression, respectively. The 2^− ΔΔCT^ method was used to analyze the relative mRNA and miRNA expressions.

2.10. Protein Extraction and Western Blot Analysis {#s0075}
--------------------------------------------------

Cultured myoblasts were washed with PBS and homogenized with radioimmune precipitation assay buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS). Protein concentrations were determined using Pierce BCA Protein Assay Reagent (Pierce Biotechnology, Rockford, IL). Proteins were separated by 10% SDS-PAGE, electrotransferred onto PVDF membrane (Millipore Corporation, Billerica, MA), and incubated with specific primary antibodies. Igf-1rβ (C20) and Gapdh (6C5, RRID: [AB_627679](nif-antibody:AB_627679){#ir0025}) antibodies were from Santa Cruz; Akt (\#9272, RRID: [AB_329827](nif-antibody:AB_329827){#ir0030}) and pAkt (Ser473) (\#9271, RRID: [AB_329825](nif-antibody:AB_329825){#ir0035}) antibodies were from Cell Signaling. Immunodetection was performed using enhanced chemiluminescence (ECL) Western blotting substrate (Pierce Biotechnology, Rockford, IL) and detected with FluoChem R imaging system (ProteinSimple, CA).

2.11. Statistical Analysis {#s0080}
--------------------------

The data are presented with mean and standard deviation (SD). *P*-values were calculated using unpaired two-tailed Student\'s *t*-test. *P*-values \< 0.05 were considered to be statistically significant.

3. Results {#s0085}
==========

3.1. Generating *MyoD*-Knockout C2C12 Clones {#s0090}
--------------------------------------------

C2C12 cells are well-established myogenic progenitors that also have some limited capacity to differentiate into adipocytes ([@bb0205]). In order to investigate the role of MyoD in myogenic *versus* adipogenic fate determination, we sought to knockout (KO) *MyoD* in C2C12 cells using the CRISPR-Cas9 technique. To improve the targeting efficiency, we first established C2C12 cells stably overexpressing Cas9 (C2C12^Cas9^), and then transfected the cells with two *in vitro* transcribed guide RNAs (gRNAs) targeting the exon 1 of *MyoD* ([Fig. 1](#f0005){ref-type="fig"}a). Two cleaved bands were only visible in C2C12^Cas9^ myoblasts transfected with both gRNAs (Fig. S1a). We sequenced the 300 bp band, and found a 336 bp deletion in *MyoD* ([Fig. 1](#f0005){ref-type="fig"}b), indicating that both gRNAs work efficiently with Cas9 to edit *MyoD*.Fig. 1Loss of MyoD facilitates the adipogenic transdifferentiation of C2C12 myoblasts. (a) Schematic diagram of MyoD partial protein coding region and the 2 targeting loci of MyoD sgRNA. The targeting loci are in red. (b) DNA sequence map around the targeting locus of the cleaved band amplified from myoblasts transfected with both gRNAs. (c) Immunostaining of MyoD (Red) and DAPI (Cyan) in control and MyoD^KO^ C2C12 myoblasts. (d) Representative images of ORO staining of C2C12 myoblasts after adipogenic differentiation. (e and f) qPCR analysis of *Myog* (e) and adipogenic markers genes (f). Error bars represent mean with SD of five independent biological replicates.^⁎^*P* \< 0.05 (Student\'s *t*-test).Fig. 1

To minimize genome-wide off-target mutations, we only cloned the sequence of Target 1 ([Fig. 1](#f0005){ref-type="fig"}a) to the plasmid PX459 to establish *MyoD*-knockout clones. Of the 21 cell clones established, we found through sequencing that most clones had mutations in one of the two *MyoD* alleles, with two clones containing 1-bp or 11-bp frame-shifting deletions in both *MyoD* alleles (Fig. S1b). These mutations resulted in truncated MyoD proteins of 55 and 72 amino acid residues lacking the basic Helix-loop-Helix domain, respectively (Fig. S1b). We further performed immunohistochemistry staining on the MyoD^KO^ cell clones using a well-established MyoD antibody. Control C2C12 myoblasts exhibited strong MyoD signals, whereas both MyoD knockout cell clones lost the MyoD signal ([Fig. 1](#f0005){ref-type="fig"}c). The T7EN1 cleavage assays showed that no genetic modification was detected at the selected off-target sites (Fig. S1c). Therefore, we have successfully established two clones of MyoD knockout C2C12 cells. We named them MyoD^KO^ C2C12 cells to distinguish them from MyoD^−/−^ primary myoblasts isolated from skeletal muscles of MyoD mutant mice.

3.2. Loss of MyoD Facilitates Adipogenic Transdifferentiation of C2C12 Myoblasts {#s0095}
--------------------------------------------------------------------------------

Consistent with previous report that MyoD^--/--^ primary myoblasts have reduced differentiation potential ([@bb0045], [@bb0055], [@bb0180]), the MyoD^KO^ C2C12 cells showed differentiation defect when induced in myogenic differentiation medium (Fig. S1d). To examine the adipogenic potential of the MyoD^KO^ C2C12 myoblasts, we exposed confluent cultures to an adipogenic differentiation medium. The control cells showed elongated morphology characteristic of myotubes, whereas many MyoD^KO^ cells differentiated into round, lipid droplet-containing adipocyte-like cells ([Fig. 1](#f0005){ref-type="fig"}d). Oil Red O (ORO) staining for neutral triglycerides revealed that control cells only had a few oil droplets. In contrast, MyoD^KO^ cells exhibited large regions of cells containing widespread oil droplets ([Fig. 1](#f0005){ref-type="fig"}d). The mutation of MyoD also dramatically downregulated the myogenic marker gene *Myog* ([Fig. 1](#f0005){ref-type="fig"}e), but significantly upregulated the adipogenic marker genes *Fabp4*, *Fasn* and *Cebpα* by 6-14 fold ([Fig. 1](#f0005){ref-type="fig"}f), indicating loss of MyoD facilitates adipogenic transdifferentiation of C2C12 cells.

As MyoD regulates *miR-133* ([@bb0160]), which targets *Igf1r* ([@bb0065]), we hypothesize that loss of MyoD upregulates *Igf1r* and consequently amplifies the downstream PI3K--Akt signaling to promote adipogenesis ([Fig. 2](#f0010){ref-type="fig"}a). Indeed, MyoD^KO^ cells expressed significantly lower levels (\~ 90% reduction) of *miR-133a* and *miR-133b* ([Fig. 2](#f0010){ref-type="fig"}b), accompanied by 2-fold increase in the expression of Igf1r both at mRNA and protein levels ([Fig. 2](#f0010){ref-type="fig"}c and d). Within two days after incubation with adipogenic induction media, MyoD^KO^ cells had increased levels of the phosphorylated Akt (pAkt), but normal levels of total Akt ([Fig. 2](#f0010){ref-type="fig"}d). In parallel to the activation of Akt, the levels of adipogenic marker genes (*Fabp4*, *Cebpα* and *Fasn*) were 2-3 fold higher in MyoD^KO^ cells than in control cells ([Fig. 2](#f0010){ref-type="fig"}e and f).Fig. 2The miR-133/Igf1r/Akt signaling pathway mediates adipogenesis of MyoD^KO^ cells. (a) Hypothetical model showing how MyoD^KO^ induces adipogenic transdifferentiation of C2C12 myoblasts. (b and c) qPCR analysis of miR-133 (b) and Igf1r (c). (d) Western blot analysis of the expressions of Igf1r and pAkt in control and MyoD^KO^ myoblasts. (e) Strategies to examine the role of PI3K and Akt in transdifferentiation of myoblasts to adipocytes. (f) qPCR analysis of adipogenic marker genes under different treatments. Error bars represent mean with SD of five independent biological replicates.^⁎^*P* \< 0.05 (Student\'s *t*-test).Fig. 2

To examine if miR-133 reduction mediates adipogenesis of MyoD^KO^ cells, we overexpressed miR-133a in cultured MyoD^KO^ cells (Fig. S2a). Electroporation-mediated gene transfer resulted in up to 840-fold elevation in the expression of miR-133a (Fig. S2a). As a consequence, the mRNA levels of *Igf1r*, *Fabp4*, *Fasn* and *Cebpα* in MyoD^KO^ cells were normalized to those in control cells (Fig. S2b). To determine if activation of PI3K--Akt is required for the adipogenic conversion of C2C12 myoblasts, the MyoD^KO^ cells were transfected with a plasmid expressing the dominant negative Akt mutant (K179M), or incubated with a PI3K inhibitor LY294002 ([Fig. 2](#f0010){ref-type="fig"}e). Both treatments normalized the mRNA levels of *Fabp4*, *Fasn* and *Cebpα* in MyoD^KO^ to similar levels as the control cells ([Fig. 2](#f0010){ref-type="fig"}f), indicating that PI3K--Akt activation is required for the upregulation of adipogenic gene expression in MyoD^KO^ C2C12 cells. Together, loss of MyoD facilitates adipogenic transdifferentiation of C2C12 cells through miR-133/Igf1r/Akt signaling pathway.

3.3. Loss of MyoD Facilitates Brown Adipogenic Transdifferentiation of Satellite Cells {#s0100}
--------------------------------------------------------------------------------------

Brown adipocytes and muscle satellite cells share a common developmental origin ([@bb0195]). As the loss of MyoD in C2C12 myoblasts facilitates adipogenic transdifferentiation, we hypothesize that loss of MyoD may convert satellite cells to brown adipocytes. To test this hypothesis, we examined cultured primary myoblasts derived from skeletal muscle satellite cells of MyoD^−/−^ mice. Under growth conditions, MyoD^−/−^ myoblasts expressed slightly increased levels of *Myf5* and strikingly reduced levels of *Myog* and miR-133 ([Fig. 3](#f0015){ref-type="fig"}a). Consistence with the reports that miR-133 targets *Prdm16* ([@bb0095], [@bb0220], [@bb0255]), this reduced levels of miR-133 is associated with increased expression of *Prdm16* in MyoD^−/−^ myoblasts ([Fig. 3](#f0015){ref-type="fig"}a). Interestingly, the expression of *Pparγ2*, a key transcriptional factor for adipogenesis ([@bb0215]), was decreased in MyoD^−/−^ myoblasts ([Fig. 3](#f0015){ref-type="fig"}a). However, the expression of several adipogenic marker miRNAs did not change their expression in MyoD^−/−^ myoblasts ([Fig. 3](#f0015){ref-type="fig"}a). These results support that MyoD KO does not spontaneously promote adipogenesis in the absence of adipogenic induction ([@bb0005]).Fig. 3Loss of MyoD dramatically downregulates miR-133a, promotes brown adipocyte biogenesis and stimulates transdifferentiation of myoblasts into brown adipocytes. MyoD^iCre/+^ mice were intercrossed to generate MyoD^iCre/iCre^ (MyoD^−/−^) knockout mice and WT littermates. The miRNA miR-133a; Prdm16 targets miR-193b and miR-365; adipogenic marker miR-143 and brown adipogenic marker miR-455 were analyzed by qPCR. (a) qPCR analysis of WT and MyoD^−/−^ myoblasts for myogenic markers *Myf5* and *Myogenin*, adipogenic markers *Pparγ2* and *Prdm16*, and the miRNAs. (b) WT and MyoD^−/−^ myoblasts were subjected to adipogenic induction and differentiation as shown in the schematics. (c) Representative images of ORO staining of adipocytes. (d and e) qPCR analysis of adipogenic markers (d) and miRNAs (e). Passage 3 primary myoblasts (purity \> 95%) from MyoD^−/−^ and WT mice were used. Error bars represent mean with SD of 3--5 independent biological replicates.^⁎^*P* \< 0.05, ^⁎⁎^*P* \< 0.01 (Student\'s *t*-test).Fig. 3

We next examined if MyoD^−/−^ myoblasts can transdifferentiate into brown adipocytes under adipogenic differentiation medium containing 1 μM Rosiglitazone, a Pparγ activator ([Fig. 3](#f0015){ref-type="fig"}b). Strikingly, MyoD^−/−^ myoblasts robustly differentiated into lipid-filling adipocytes as indicated by ORO staining ([Fig. 3](#f0015){ref-type="fig"}c). In contrast, wild-type (WT) myoblasts did not transdifferentiate into adipocytes under identical culture conditions ([Fig. 3](#f0015){ref-type="fig"}c). After differentiation, brown adipogenic markers genes *Prdm16*, *Ucp1* and *Lhx8* were expressed 16-fold, 30-fold and 100-fold higher in MyoD^−/−^ cells than in WT cells ([Fig. 3](#f0015){ref-type="fig"}d). The adipogenic master regulator *Pparγ2* was expressed 30-fold higher in MyoD^−/−^ cells as well ([Fig. 3](#f0015){ref-type="fig"}d). The level of miR-133a remained low in MyoD^−/−^ cells after adipogenic differentiation ([Fig. 3](#f0015){ref-type="fig"}e). However, the Prdm16 target miR-193b was upregulated by 7-fold, and adipogenic miR-143 and miR-455 were 17-fold and 8-fold higher, respectively, in the MyoD^−/−^ cells compared with the WT cells ([Fig. 3](#f0015){ref-type="fig"}e). We conclude from these results that the loss of MyoD downregulates miR-133a, upregulates *Prdm16*, and promotes the transdifferentiation of myoblasts into brown adipocytes under adipogenic conditions.

3.4. Loss of MyoD Facilitates Adipogenic Transdifferentiation of Myoblasts *in vivo* {#s0105}
------------------------------------------------------------------------------------

To investigate the adipogenic potential of MyoD^KO^ C2C12 myoblasts *in vivo*, control and MyoD^KO^ C2C12 cells were injected into injured TA muscles of mdx mice, which lack the expression of dystrophin, a muscle membrane protein. Eight days after cell transplantation, TA muscles injected with MyoD^KO^ C2C12 cells formed fewer dystrophin^+^ myofibers compared with muscles injected with control C2C12 cells (Fig. S3a and b). Interestingly, the reduced myogenic capacity of MyoD^KO^ cells is accompanied by a concomitant increase in formation of BODIPY-label adipocytes (Fig. S3a). Consistently, the concentration of triglycerides (TG) was 40% higher (1.5 for WT C2C12 cells and 2.1 for MyoD^KO^ C2C12 cells) in muscles grafted with MyoD^KO^ C2C12 cells compared with those injected with WT C2C12 cells (Fig. S3c). To directly trace the fate conversion of injected C2C12 cells, we used adenovirus to overexpress *GFP* in control and MyoD^KO^ C2C12 cells prior to grafting into glycerol-injected TA muscles ([Fig. 4](#f0020){ref-type="fig"}a). Eight days after cell graft, the muscles injected with MyoD^KO^ C2C12 cells had about 3-fold more GFP^+^ BODIPY^+^ cells compared with muscles injected with control C2C12 cells ([Fig. 4](#f0020){ref-type="fig"}a and b). Consistently, the expression levels of adipogenic marker genes *Fabp4* and *Cebpα* were higher in muscles injected with MyoD^KO^ C2C12 cells than in those injected with control C2C12 cells ([Fig. 4](#f0020){ref-type="fig"}c). These results indicate that loss of MyoD facilitates adipogenic transdifferentiation of C2C12 myoblasts *in vivo*.Fig. 4Loss of MyoD facilitates adipogenic transdifferentiation of myoblasts *in vivo*. (a) Immunostaining of BODIPY (red) in TA muscles injected with control or MyoD^KO^ C2C12 cells. Arrows indicate GFP^+^ BODIPY^+^ cells. (b) The ratio of BODIPY signal in GFP^+^ cells in TA muscles injected with control or MyoD^KO^ C2C12 cells. (c) qPCR analysis of adipogenic marker genes. (d) Representative images of ORO staining of regenerated TA muscles of WT and MyoD^−/−^ mice. The MyoD^−/−^ mice ([@bb0170]) were generously provided by Dr. Michael Rudnicki. (e) Relative ORO intensity on WT and MyoD^−/−^ TA muscle sections. (f) qPCR analysis of adipogenic marker genes. (g) ORO staining and *anti*-Perilipin staining in myoblasts isolated from glycerol-injured TA muscles of WT and MyoD^−/−^ mice. Arrows indicate ORO^+^ or Perilipin^+^ cells. (h) The ratio of ORO^+^ and Perilipin^+^ cells in myoblasts isolated from injured WT and MyoD^−/−^ TA muscles. Four sections were analyzed for each sample. Error bars represent mean with SD of three independent biological replicates.^⁎^*P* \< 0.05 (Student\'s *t*-test).Fig. 4

To further investigate the adipogenic transdifferentiation of MyoD^−/−^ satellite cells *in vivo*, TA muscles of MyoD^−/−^ mice and WT littermates were treated with glycerol to induce muscle degeneration and adipogenesis. On day 10 after glycerol injection, TA muscle sections were stained with ORO to label lipids ([Fig. 4](#f0020){ref-type="fig"}d). Strikingly, TA muscles of MyoD^−/−^ mice had much more pronounced ORO labeling ([Fig. 4](#f0020){ref-type="fig"}d), with a 7-fold increase in the density of ORO signal compared to WT mice ([Fig. 4](#f0020){ref-type="fig"}e). Consistently, mRNA levels of adipogenic marker genes *Fasn* and *Pparγ2* were higher in TA muscles of MyoD^−/−^ mice compared with those in WT mice ([Fig. 4](#f0020){ref-type="fig"}f). However, mRNA levels of brown adipogenic marker gene *Ucp1* were comparable in TA muscles of WT and MyoD^−/−^ mice ([Fig. 4](#f0020){ref-type="fig"}f). To confirm the satellite cell origin of the ORO^+^ cells in glycerol treated MyoD^−/−^ muscles, primary myoblasts were isolated from TA muscles using magnetic-activated cell sorting (MACS) at 4 days after glycerol injection, prior to adipogenic differentiation ([Fig. 4](#f0020){ref-type="fig"}g). Strikingly, the percentage of ORO^+^ and Perilipin^+^ myoblasts was 4-fold and 28-fold higher, respectively, in myoblasts isolated from MyoD^−/−^ mice than in the myoblasts isolated from WT mice ([Fig. 4](#f0020){ref-type="fig"}h). We conclude that loss of MyoD facilitates adipogenic transdifferentiation of satellite cell-derived myoblasts *in vivo*.

3.5. Overexpression of MyoD in BAT Preadipocytes Inhibits Adipogenesis {#s0110}
----------------------------------------------------------------------

To further examine the role of MyoD in brown adipocyte versus myoblast fate switch, we used adenoviruses to overexpress *MyoD*-*GFP* (MyoD^OE^) or *GFP* only (control) in BAT SVF preadipocytes isolated from WT mice. Two days after transduction of adenoviral vectors, brown preadipocytes were induced to undergo adipogenesis. ORO staining showed MyoD but not GFP markedly decreased lipid accumulation in brown adipocytes differentiated from BAT SVF cells ([Fig. 5](#f0025){ref-type="fig"}a). We also utilized BODIPY to label brown adipocytes ([Fig. 5](#f0025){ref-type="fig"}b and c). Whereas 82% (387 out of 473) of GFP^+^ cells were BODIPY^+^ in the control group, only 13% (55 out of 426) of the GFP^+^ (indicative of MyoD^OE^) cells were BODIPY^+^ in the MyoD^OE^ group ([Fig. 5](#f0025){ref-type="fig"}d), representing a 6-fold decrease. We noticed in the MyoD^OE^ group a negative correlation between GFP and BODIPY signals: there was essentially no BODIPY signal in regions with high densities of GFP signals (Fig. S4a). In addition, a group of MyoD^OE^ brown preadipocytes showed elongated myotube-like morphologies (Fig. S4a), and about 70% (115 out of 165) of the elongated MyoD^OE^ cells expressed myosin heavy chain (MF20^+^) (Fig. S4b and c), indicating that MyoD transdifferentiates brown preadipocytes into myocyte. At the molecular level, *MyoD* overexpression was correlated with 18-fold and 288-fold elevation in the expression of *Myog* and *eMHC*, respectively ([Fig. 5](#f0025){ref-type="fig"}e). In parallel, the expression levels of miR-133a and miR-133b were upregulated by 28-fold and 30-fold, respectively ([Fig. 5](#f0025){ref-type="fig"}f). By contrast, brown adipogenic marker genes *Prdm16* and *Ucp1* were decreased by 92% and 70%, respectively, and other adipogenic marker genes *Fabp4*, *Adipoq* and *Cebpα* were also downregulated by 82%, 81% and 69%, respectively ([Fig. 5](#f0025){ref-type="fig"}g). Together, our data indicate that BAT adipogenesis is inhibited by ectopic expression of *MyoD*.Fig. 5Overexpression of MyoD impairs brown adipogenesis of wildtype BAT SVF cells. (a) ORO staining of brown adipocytes differentiated from wildtype BAT SVF cells transduced with control or MyoD^OE^ adenovirus. (b and c) Immunostaining of BODIPY (red) in control (b) and MyoD^OE^ (c) brown adipocytes (d) The ratio of BODIPY signal in GFP^+^ cells in control and MyoD^OE^ brown adipocytes. Five different areas analyzed in each experiment. (e--g) qPCR analysis of myogenic markers (e) miRNAs (f) and adipogenic markers (g). Error bars represent mean with SD of three independent biological replicates.^⁎^*P* \< 0.05 (Student\'s *t*-test).Fig. 5

3.6. Deletion of miR-133a Blunts the Inhibitory Effect of MyoD on Brown Adipogenesis {#s0115}
------------------------------------------------------------------------------------

To investigate whether miR-133 mediates the inhibitory effect of MyoD on adipogenesis, we used adenoviral vectors to overexpress *MyoD* in miR-133a1/a2 double knockout (miR-133a^−/−^) BAT SVF cells. MyoD overexpression decreased lipid accumulation in miR-133a^−/−^ brown adipocytes differentiated from BAT SVF cells ([Fig. 6](#f0030){ref-type="fig"}a), but to a much lesser extent compared with the level of decrease in WT brown adipocytes ([Fig. 5](#f0025){ref-type="fig"}a). By labeling brown adipocytes with BODIPY ([Fig. 6](#f0030){ref-type="fig"}b and c), we found that 82% (420 out of 512) of GFP^+^ cells were BODIPY^+^ in the control group, and 48% (229 out of 476) of the GFP^+^ cells were BODIPY^+^ in the MyoD^OE^ group ([Fig. 6](#f0030){ref-type="fig"}d), representing \< 2-fold decrease ([Fig. 6](#f0030){ref-type="fig"}e). By contrast, MyoD decreased the ratio of GFP^+^/BODIPY^+^ cells by over 6-fold in WT brown adipocytes ([Fig. 6](#f0030){ref-type="fig"}e). *MyoD* overexpression similarly increased the levels of miR-133b by 30-fold in both WT and miR-133a^−/−^ brown adipocytes (Figs. 6f and 5f). In addition, MyoD overexpression increased the levels of *Myog* and *eMHC* to similar extent in WT and miR-133a^−/−^ brown adipocytes ([Fig. 6](#f0030){ref-type="fig"}g), suggesting that MyoD induces myogenesis independent of miR-133a. However, the extent of MyoD-induced suppression of adipogenic markers was much lesser in the miR-133a^−/−^ compared to WT brown adipocytes ([Fig. 6](#f0030){ref-type="fig"}h). Specifically, the MyoD overexpression induced fold decreases of *Fabp4*, *Adipoq*, *Cebpα*, *Ucp1* and *Prdm16* were 5-fold, 5-fold, 3-fold, 14-fold and 3-fold, respectively, in WT brown adipocytes ([Fig.6](#f0030){ref-type="fig"}h). In contrast, in the absence of miR-133a, MyoD only decreased the expression of these genes by 1.6-fold, 2-fold, 1.5-fold, 3-fold and 1.5-fold, respectively ([Fig. 6](#f0030){ref-type="fig"}h). These results demonstrate that MyoD inhibits brown adipogenesis partly through miR-133a.Fig. 6Loss of miR-133a alleviates the inhibitory effect of MyoD on brown adipogenesis. (a) ORO staining of brown adipocytes differentiated from miR-133a^−/−^ BAT SVF cells transduced with control or MyoD^OE^ adenovirus. (b and c) Immunostaining of BODIPY (red) in control (b) and MyoD^OE^ (c) miR-133a^−/−^ brown adipocytes. (d) Ratios of BODIPY signal in GFP^+^ cells in control and MyoD^OE^ miR-133a^−/−^ brown adipocytes. Five different areas analyzed in each experiment. (e) Fold changes of GFP^+^ BODIPY^+^ cells in WT and miR-133a^−/−^ brown adipocytes after MyoD overexpression (f) qPCR analysis of miR-133a and miR-133b. (g and h) Fold changes of myogenic markers (g) and adipogenic markers (h) in WT and miR-133a^−/−^ brown adipocytes after MyoD overexpression. Error bars represent mean with SD of three independent biological replicates.^⁎^*P* \< 0.05 (Student\'s *t*-test).Fig. 6

4. Discussion {#s0120}
=============

We identified MyoD as a negative regulator of brown adipocyte development. This result extends the function of MyoD in addition to its well-established role as a positive regulator of myogenesis. With the CRISPR-Cas9 technique, we successfully established 2 clones of MyoD^KO^ myoblasts and discovered that loss of MyoD facilitates the adipogenic transdifferentiation of C2C12 myoblasts. Consistent with our study is that downregulation of MyoD mRNA by RNaseL in C2C12 myogenic cells led to adipogenic differentiation ([@bb0185]). We show that the MyoD/miR-133/Igf1r/PI3K/Akt signaling pathway is involved in the promotion of adipogenesis in MyoD^KO^ cells. Insulin, a component of the adipogenic differentiation medium, binds to Igf1r to activate the p85 regulatory subunit of PI3K, which subsequently phosphorylates and activates Akt ([@bb0015]). Akt then inhibits tuberous sclerosis complex 2 and activate the mammalian target of rapamycin complex 1 to promote insulin-induced adipogenesis ([@bb0265]).

Loss of MyoD is necessary but not sufficient to promote brown adipogenesis of myoblasts. MyoD^−/−^ myoblasts expressed dramatically lower levels of miR-133a, which led to the upregulation of *Prdm16*, without increasing expression of *Pparγ2*, a master regulator of adipogenesis. Although Prdm16 primes brown adipogenesis ([@bb0195]), the adipogenic conversion of myoblasts requires activation of Pparγ ([@bb0250]). For example, the addition of rosiglitazone in adipogenic medium was required to activate Pparγ to execute the conversion. This also explains why MyoD^−/−^ myoblasts did not result in conversion of myoblasts to brown adipocytes spontaneously in the absence of adipogenic induction. Interestingly, although MyoD^−/−^ satellite cells can transdifferentiate into adipocytes under adipogenic conditions *in vivo*, these adipocytes are UCP1^−^. This observation suggests that additional factors, such as Notch signaling and sympathetic innervation ([@bb0010], [@bb0135]), may be required to induce UCP1 expression in the transdifferentiated MyoD^−/−^ adipocytes. A previous study reported that MyoD mutant mice have normal interscapular BAT mass ([@bb0025]). This may be due to the relative late activation of MyoD after Pax7/Myf5 during myogenesis and brown adipogenesis ([@bb0175], [@bb0190]). Therefore, deletion of MyoD should not affect brown adipogenesis, which takes place before MyoD activation in the Pax7/Myf5 progenitors.

Several myogenic factors including MyoD are expressed in brown preadipocytes, with expression diminishing during differentiation ([@bb0210]), indicating that inhibition of MyoD is required for brown adipogenesis. We demonstrate that overexpression of MyoD dramatically upregulates miR-133 expression in brown adipocytes. This is consistent with the report that MyoD binds to regions upstream of miR-133([@bb0160]). As miR-133 represses *Prdm16* ([@bb0095], [@bb0220], [@bb0255]), the MyoD/miR-133/Prdm16 signaling cascade explains the inhibitory effect of MyoD on brown adipogenesis. Forced expression of MyoD in adipocyte precursors or white adipocytes similarly inhibits adipogenic differentiation, indicating MyoD inhibits adipogenesis in general regardless of Prdm16 ([@bb0075], [@bb0245]). This is probably achieved through the transdifferentiation of brown preadipocytes into MF20^+^ myocytes and miR-133 mediated inhibition of Igf1r which is required for adipogenesis ([@bb0030]).

We show that miR-133 is an important mediator of MyoD-induced inhibition of adipogenesis. There are two mature miR-133 isomers: miR-133a and miR-133b that only differ in one nucleotide. The miR-133a is encoded by two genes (*miR-133a1* and *miR-133a2*), and double mutant mice exhibit cardiac and skeletal muscle myopathy, along with browning of subcutaneous white adipose tissue ([@bb0090], [@bb0085], [@bb0095]). By contrast, the miR-133b mutant mice are normal ([@bb0020]), indicating that miR-133a has more important physiological functions than miR-133b. The observation that deletion of miR-133a only partially blocked the inhibitory function of MyoD on brown adipogenesis suggests that additional factors are involved in mediating MyoD function in brown adipocytes. It is possible that the residual miR-133b partially compensated for the miR-133a loss-of-function. Our finding that ectopic expression of MyoD inhibits brown adipogenesis and promotes myogenic transdifferentiation suggests that inhibition of myogenesis is necessary for brown adipogenic commitment of Pax7/Myf5 progenitors. As MyoD KO alone is insufficient to block embryonic myogenesis, the brown adipocyte development is not affected. Supporting this notion, complete blockage of myogenesis in MyoD/Myf5 and MyoD/Igf2 double knockout mice both exhibit more pronounced adipogenesis ([@bb0025], [@bb0070]). MyoD inhibits adipogenesis and the expression of *Prdm16*, and Prdm16 reciprocally inhibits myogenesis and the expression of *MyoD* ([@bb0195]). The mutual exclusion of the two master regulators balances and determines the developmental separation of BAT and muscle progenitors during embryogenesis.

In summary, our results establish MyoD as a negative regulator of brown adipocyte development through upregulating miR-133 to suppress *Igf1r* and *Prdm16* ([Fig. 7](#f0035){ref-type="fig"}). Our work suggests that inhibition of MyoD in patient-derived myoblasts may promote their transdifferentiation into brown adipocytes.Fig. 7Diagram summarizing the role of MyoD in brown adipocyte and myoblast fate determination. Loss of MyoD stimulates transdifferentiation of myoblasts into brown adipocytes. Conversely, overexpression of MyoD inhibits brown adipogenesis through myogenic transdifferentiation of brown adipocytes and miR-133-mediated mRNA decay of *Prdm16* and *Igf1r*.Fig. 7
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